Bliss GVS Pharma Share Price Today

Bliss GVS Pharma pledges 47.95% equity stake to Catalyst Trusteeship

Pledged 5,09,84,595 equity shares to Catalyst Trusteeship Limited. Encumbrance covers 47.95% of total voting capital. Transaction date recorded as September 30, 2026. Trustee acts on behalf of debenture holders.

Bliss GVS Pharma board approves ESOP 2026 plans for employees

Board approved Senior Executive and Employee ESOP 2026 policies on October 1, 2026. Senior Executive plan covers 26,50,000 shares (~2.49% of capital) at ₹10 exercise price. General Employee plan covers 47,00,000 shares (~4.42% of capital) at ₹10 exercise price. Approvals subject to shareholder consent and SEBI SBEB Regulations, 2021 compliance.

Bliss GVS Pharma promoters reclassified to public after Anupam Rasayan takes control

Bliss GVS Pharma promoters reclassified to public following control transfer. Anupam Rasayan and PAC hold 50.07% combined equity post-acquisition. PAC acquired 47.95% stake via Share Purchase Agreement; Anupam Rasayan held 2.12% prior. Outgoing promoter group stake reduced from 34.82% to 0.01%. Board appointed three new Non-Executive Non-Independent Directors aligned with new management.

Bliss GVS Pharma shareholders approve Santosh Parab director appointment

Santosh Parab appointed as Non-Executive Non-Independent Director via postal ballot. Total votes in favour stood at 60,481,459, representing 97.04% of votes polled. Public institutions recorded 15.53% opposition, contrasting with near-unanimous retail support. Voting period ran from August 21, 2026, to September 19, 2026, via CDSL e-voting.

Bliss GVS Pharma seeks shareholder approval for Santosh Parab director role

Bliss GVS Pharma seeks shareholder approval for Santosh Parab's director appointment. Parab will serve as non-executive, non-independent director. Remote e-voting opens August 21, 2026, and closes September 19, 2026. Results to be declared on or before September 22, 2026.

Bliss GVS Pharma Q1 Results: Consolidated net profit rises 83% YoY to ₹513.7 lakh

Bliss GVS Pharma delivered robust Q1FY27 results with consolidated net profit surging 83% YoY to ₹513.72 lakh, aided by a 21% revenue increase to ₹2,951.75 lakh. Standalone metrics showed even stronger momentum, with profit up 83% and revenue rising 32%. Margin expansion drove outsized profit growth relative to top-line gains.